Regulus Therapeutics in Deal With Sanofi-Aventis

Carlsbad-based Regulus Therapeutics, a biopharmaceuticals firm focused on microRNA, and Sanofi-Aventis, said today that the two are in a global strategic alliance worth potentially over $750 million. The two said that the deal includes a $25M upfront free, a $10M future equity investment, and annual research support for three years with option for two additional years. The two will collaborate on four microRNA target programs. The companies also said Sanofi-aventis has an option to expand development and commercialization of their efforts, which is worth an additional $50M to Regulus. Regulus is a joint venture of Alynylam Pharmaceuticals and Isis Pharmaceuticals.